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ing patients with rare diseases, and studying attitudes and behaviours relating to 
taboo subjects. SM may also increase recruitment into research studies, especially 
from hard-to-reach groups.
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PHarmaco-Economic Education nEEds invEstigatEd by isPor cHaPtEr 
– ExamPlE from bulgaria
Nikolov I.1, Petrova G.2
1Glaxo SmithKline, Sofia, Bulgaria, 2Medical University of Sofia, Sofia, Bulgaria
Objectives: Education in pharmacoeconomics is one of the primary goals of ISPOR. 
This study is aiming to explore the needs for pharmacoeconomic educations by 
national chapter among different pharmaceutical stakeholders. MethOds: Inquiry 
research was performed among the participants in 2 educational initiatives of the 
Bulgarian ISPOR chapter. In both seminars attended representatives of payers - 
Bulgarian government (MoH, NHIF), as well as from pharmaceutical business, non- 
governmental organizations and academia. On total 48 individuals left feedback from 
over 60 participants in both seminars. The questionnaires focused on the topics cov-
ered in the seminars, organizational matters and needs of new educational themes. 
Preferred themes were assessed and results are consolidated Results: Both semi-
nars target the same groups of individuals – institutions, academia, pharmaceutical 
business, and non-governmental organizations. The first seminar was focused mainly 
on the pricing and reimbursement of the pharmaceuticals with international lectur-
ers, while the second one covered basic pharmacoeconomic methods with national 
lectures. The overall satisfaction score from both seminars was very high (25%) and 
excellent (55%). The most preferred topic was the pricing and reimbursement of phar-
maceuticals by 53%, followed by different modeling techniques (47%). Participants 
wanted to know more about the way of regulatory usage of pharmacoeconomics in 
pricing and reimbursement (70%). Focus groups discussion (98%) and practical of 
pharmacoeconomic were also a matter of high preference (30%). cOnclusiOns: This 
study proves the necessity for education in the field of pharmacoeconomic, modeling, 
core models explanations and pharmaceuticals assessment. They also pointed out 
the place of national chapters as providers of education and independent organizers 
able to gather different stakeholders’ point of view in non-formal discussions. Having 
in mind that BG is in the beginning of the HTA process obviously willingness to be 
educated among the whole Pharma environment is definitely high.
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PHarmacoEconomic Education for HEaltH carE studEnts in bosnia 
and HErzEgovina
Catic T.
ISPOR Bosnia and Herzegovina, Sarajevo, Bosnia
Objectives: In order to examine the current situation related to education in the 
field of pharmacoeconomics and Health-economics, we investigate which uni-
versities and colleges provide such training. The study included pharmaceutical, 
medical and dentistry faculties and departments as well as the health care col-
leges. Information on health care colleges and faculties in B&H are taken from State 
register of accredited higher education institutions. MethOds: We have analyzed 
the on-line availability of the curricula at official websites of health care faculties, 
its content for each program of study at the undergraduate and postgraduate level. 
All programs are qualitatively analyzed in terms if they include pharmacoeco-
nomics/health economics as a separate subject (mandatory or elective) Results: 
Twenty-two high health care institutions are identified; 5 medical, 4 dentistry, 9 
pharmaceutical faculties, 13 nursing and 6 othe. Seventeen of them have on-line 
available curricula, 3 are not available and 2 faculties do not have available web-
sites, so we included 77,7% of all health care faculties program. In undergraduate 
courses pharmacoeconomics/health-economics is included in curricula at 5 facul-
ties. Pharmacoeconomics as separate mandatory subject is included in curricula 
at 1 medical and 1 pharmacy faculty while at 3 health care colleges this area is 
covered through health-economics or health-management courses. In postgraduate 
programs (master and doctoral studies) just 3 faculties included health economics 
in its curricula; 1 medical faculty as mandatory subject, and 2 medical colleges 
as elective subject. cOnclusiOns: Pharmacoeconomic education for health care 
students in Bosnia and Herzegovina is poorly organized and not satisfactory. There 
is growing need to educate health care professional and stakeholders in this field to 
ensure proper understanding and implementation in practice and decision-making 
process. Limitation of this study is that detail programs and structure of courses 
could not be examined since it is not on-line available. Further research is recom-
mended to get deep insight into curricula.
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Objectives: To validate an innovative experience that aims at being recognized 
by Institutions as a national and independent HTA assessor, thus supporting both 
national and regional health care decison makers. This experience consists of 
a multi-stakeholder working group that, in the field of new technologies pro-
posed for critical clinical areas, discusses and develops guide-lines and decision 
rules and comparatively examines local data. MethOds: The working method 
consists of a series of meetings (4 per year) of a scientific board (composed 
by high-profile experts covering all HTA domains) that carries out a nationwide 
analysis of the topic under examination and focuses on the main clinical, eco-
nomic, organizational, social, and ethical aspects. Questionnaire-based surveys 
and Delphi panel are the main operational tools. WEF adopts standard HTA pro-
17.4% of all abstracts were in the Alergy diseases area. It was followed by Multiple 
Diseases (14%). cOnclusiOns: It was shown that the policy changing in 2008 as 
to require pharmacoeconomics dossiers in the reimbursement application effected 
Turkey specific pharmacoeconomic and health outcome studies positively. In other 
words, pharmaceutical ýndustry and the government started to invest in pharma-
coeconomics and health outcome studies after 2008.
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long tErm analisys of tHE Hungarian HosPital bEd caPacitiEs
Ágoston I., Szarka E., Endrei D., Zemplényi A., Molics B., Vas G., Boncz I.
University of Pécs, Pécs, Hungary
Objectives: To provide a long term analysis of the Hungarian hospital bed capaci-
ties. MethOds: During the preparation we performed bibliographic review includ-
ing research of related statistical data collections, historical hospital works. Data 
were derived from the database of the Hungarian Central Statistical Office and 
from historical documents. The study covered the period between 1800-2010. The 
following indicators were used: number of hospitals and hospital beds. Results: 
The first data available for hospital statistics dates back to 1800 and showed that 
there were 34 hospitals and 1590 hospital beds in Hungary. For 1867 the number of 
hospitals and hospital beds increased up to 46 and 4684 respectively. Shortly after 
the introduction of compulsory health insurance in 1891, the number of hospitals 
was 344 and the number of hospital beds was 16497 in 1895. After the First World 
War hospital number decreased to 183, and bed number increased to 26451. Since 
1945 to 1990 the number of hospitals varied between 147-287, while the number 
of hospital beds continuously increased from 33162 to 105097. After the social and 
political changes in 1990, hospital bed number showed strong decrease to 71216 in 
2010 with varying number of hospitals between 148-174. As a consequence in the 
changes of numbers of hospitals and hospital beds, the average bed number per 
one hospital continuously increased from 47 in 1800, 107 in 1915, 182 in 1950 and 
710 in 1990. cOnclusiOns: The definition and function of hospitals significantly 
changed during the past 200 years in Hungary. The former old fashioned small poor 
houses of the early 19th century have been replaced by hospitals with large number 
of hospital beds by 1990. After social and political changes in 1990, the number of 
hospitals beds in Hungary decreased and got closer to EU average.
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‘big data’ in HEaltH carE. WHat doEs it mEan and Will it makE a 
diffErEncE?
Velthuis E.J.1, Malka E.S.2, Richards M.S.2
1PPD, Bennekom, The Netherlands, 2PPD, Morrisville, NC, USA
bAckgROund: With the evolution from data on paper into electronically available 
data, the term Big Data has made its entrance. This term is widely used and refers 
to the four V’s: Volume, Velocity, Variety and Veracity. Big Data is being used in many 
sectors such as retail and banking, and also in the health care sector. However, within 
the health care sector, this term is ill defined. Objectives: The main purpose of this 
study is to get an understanding of the definition of Big Data in health care. Further, 
it’s value and challenges will be explored. MethOds: : First, an attempt has been 
made to clarify the term Big Data in health care using the term “Big Data” in combina-
tion with ‘health’ in PubMed searches. Also, the internet and social media have been 
searched for definitions of Big Data in health care. Further, the potential use of Big 
Data in health care has been reviewed using these sources. Results: In the medical 
literature, the term Big Data is rarely used in health care research and no standard 
definitions of Big Data big data are available. The term is used in combination with 
electronic health care records (EHR), claims data, registries, pharmacy utilization 
records, and linkages between these databases. On the internet and social media, 
various definitions for Big Data in the health care sector can be found.” Values are: 
increased medical knowledge, improved quality of care, improved personalized medi-
cine, better health outcome prediction, and lower costs. Challenges with Big Data in 
Healthcare are of technical (different data structures), ethical (patient privacy) and 
scientific (quality issues, biases, causality assessment) magnitude. cOnclusiOns: 
Healthcare Big Data has poorly been defined. Use of Big Data can be beneficial in terms 
of better care and lower costs despite the challenges to be faced.
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disEasE bEcomEs social. HEaltH rEsEarcH conductEd on, or using, 
WEb 2.0 mEdia: a systEmatic rEviEW
Martin A., Lombard L.
Evidera, London, UK
Objectives: To assess the range and focus of health research that has involved 
interactive internet and mobile technology (“social media”; SM). MethOds: We 
conducted a systematic review of studies that investigated the use of SM, or used 
SM as a research tool, published in English since 2003 and indexed in MEDLINE 
and EMBASE. Results: We identified 3,773 unique studies, of which 304 reported 
primary research or were systematic reviews of such studies. Of these, 192 (63%) 
were surveys of actual or potential users of SM, including health care professionals 
(20%), patients with a specific disease or problem (46%), or the general public (34%); 
40 (13%) were articles describing SM tools or sites; 71 (23%) assessed the potential 
of SM to increase knowledge or improve clinical outcomes, of which 22 compared 
SM with more traditional support or information; 71 (23%) described SM users; 
53 (17%) sought their views on the benefits of SM; 24 (8%) discussed the potential 
harm its use could do to professional-patient relationships; and 25 (8%) analysed 
SM content. SM were also used as a tool to recruit participants into research (85 
articles, 28%), especially on topics such as sexual practices, intimate partner vio-
lence, or substance abuse, or involving groups typically underrepresented in clinical 
research. Of the various types of SM studied or used to recruit participants into 
research, Facebook was cited in 73 articles (24%); mobile apps in 40 papers (13%); 
PatientsLikeMe and Twitter in 13 articles (4%) each; MySpace in 3 articles (1%); and 
other online forums in 70 articles (23%). cOnclusiOns: SM is a rich source of data 
on patients and health care professionals. It may be particularly useful in target-
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but rather where list prices are lower than in comparable countries. Objectives: 
The aim of this research is to understand the impact of H2H data on the Service 
Médical Rendu (SMR) and Amélioration du Service Médical Rendu (ASMR) ratings fol-
lowing passage of the law. MethOds: Transparency Commission (TC) reports for new 
drugs or indication expansions of existing drugs published between January 1, 2012 
and March 31, 2013 were reviewed. The following data were gathered: 1) study type 
(placebo-controlled vs active H2H comparator); 2) comparator (if H2H); 3) availability 
of appropriate comparators in the marketplace; and 4) SMR/ASMR ratings. Results: 
A total of 110 TC assessments of 88 drugs were identified and examined. Ninety-four 
of the 110 assessments were of drugs where an appropriate comparator existed in the 
marketplace. Of these 94 assessments, H2H trials were conducted in 54 assessments. 
The percentage of assessments in the H2H group obtaining an SMR of important (78%) 
was similar to those that did not conduct H2H trials (75%). In contrast, the percent-
age of assessments in the H2H group obtaining an ASMR of III or IV was greater than 
the non-H2H group (15% vs. 26%). cOnclusiOns: The conduct of H2H trials does 
not guarantee an SMR of important for new drugs or indication extensions, but may 
improve ASMR rating. Although the TC mentions the lack of comparative data as a 
major contributing factor for an SMR of insufficient in their assessments of some 
products (Daxas, Xiapex), other factors, such as adverse events or efficacy data vs 
placebo are equally important.
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influEncE of PatiEnt-rEPortEd outcomEs on Hta rEimbursEmEnt 
dEcisions
Kulich K.1, Versoza L.2, Jaksa A.2, Demuro-Mercon C.3, Gnanasakthy A.4
1Novartis Pharma AG, Basel, Switzerland, 2Context Matters, Inc., New York, NY, USA, 3RTI Health 
Solutions, Research Triangle Park, NC, USA, 4Novartis Pharmaceuticals, East Hanover, NJ, USA
Objectives: To understand how patient-reported outcomes (PROs) influence deci-
sions made by Health Technology Assessment (HTA) agencies. MethOds: Reports 
from five HTA agencies that make reimbursement decisions (NICE, HAS, SMC, PBAC 
and CADTH’s CDR) were selected. The reports, taken from January 2005-April 2013, 
cover disease conditions in neurological and respiratory therapeutic areas. PROs 
within the HTA reports were identified and four analysts independently examined 
the stated rationales for the agencies’ decisions to determine whether PROs had a 
positive, negative, or neutral influence on the decision. Discrepancies between the 
analysts were discussed in-depth until consensus was reached. Results: A total of 
262 HTA reports were analyzed from the five agencies selected. PROs were mentioned 
in 34% of the HTA reports, and were the primary endpoint in 6%. Twenty-five (10%) 
reports mentioned PRO in the clinical rationale for their decisions. Twelve of the 25 
HTA reports (48%) contained PRO as a primary outcome, indicating that a PRO is more 
likely to influence the decision-making process if it is a primary outcome (p < 0.001). In 
12 out of the 25 HTA reports, the clinical rationale for the decision stated that, for the 
PRO, the drug performed better than placebo or comparator. Ten (83%) of these reports 
resulted in a positive decision. In eight reports, the drug compared equivalently or 
unfavorably to placebo or comparator for the PRO and resulted in four (50%) positive 
decisions. There was no significant difference in agency decisions between the reports 
that positively reported PROs and the reports with negative or similar PRO results 
(p= 0.16). cOnclusiOns: In respiratory and neurological diseases, the use of PROs 
is more likely to influence decision-making by HTA agency when PROs are specified 
as primary outcomes. Future research directions include comparing these findings 
to the effect other clinical outcomes have on reimbursement decisions.
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Objectives: To compare data requirements and their availability for HE evaluations 
in 5 countries in Central/Eastern Europe - Poland, Czech Republic, Slovakia, Hungary, 
Romania (CEE) and 5 in Western Europe – UK, France, Germany, The Netherlands, 
Sweden (WE). MethOds: A questionnaire was developed and distributed to market 
access representatives from Pfizer who were asked to complete the questionnaire 
with opinion leader’s support. The questionnaire focused on the obligation to con-
duct HE assessment for reimbursement submissions, local HE guidelines, applied 
discount rates for future costs and effects, willingness to pay (WTP) thresholds 
and available data sources. Results: HE is mandatory in all CEE and 3 WE par-
ticipating countries for reimbursement applications of innovative drugs. Usually 
cost-effectiveness (CEA) and budget-impact (BIA) analyses are required. The pre-
ferred outcome of CEA is quality-adjusted-life years. In Romania, France and Czech 
Republic guidelines could not be identified at the time of the survey. HE evaluations 
are usually prepared by the applicant; in Sweden, UK, The Netherlands and Poland 
unlocked models have to be presented for scrutiny. Discount rates vary from 1.5% 
to 5%; usually the same for costs and outcomes (except in The Netherlands and 
Poland). Only UK, Poland and Slovakia have an explicit WTP threshold. In Poland 
it is based on GDP per capita, in Slovakia on multiples of average monthly wages. 
Differences were found on data availability. In WE data can be acquired easier com-
pared to CEE. Health insurance funds do not provide their data, unless they were 
published. Patient registries are either not available in CEE or difficult to access, so 
applicants mostly rely on retrospective medical chart data, hospital information 
systems or expert panels. cOnclusiOns: We found similar requirements for HE 
analyses in CEE and WE but differences in data availability. This results in less 
accurate inputs across the CEE influencing analyses’ outcomes.
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kEy drivErs of Pbac dEcisions for tHE rEimbursEmEnt of orPHan 
drugs on tHE lifE saving drugs Program
Maguire B., Tilden D.
THEMA Consulting Pty. Limited, Pyrmont, Australia
cedures according to the EUnetHTA Core Model. To avoid any conflict of interests, 
no fee is paid to any member. Results: Since 2011, three HTA reports have been 
completed focusing in 2011-2012 on hepatology (HCV/HBV screening and treat-
ments) and extending in 2013 to other topics including hepatocellular carcinoma 
and inflammatory bowel diseases; HIV is coming up next year. Along with 4 pub-
lications in international journals (mean impact factor 5.73), there have been 
auditions at the Italian Drug Agency (AIFA) and at the Healthcare Commission 
in Parliament that have facilitated the approval of new HCV drugs. Furthermore, 
delays in approvals by regional formularies have been reduced by about 65% 
(from 212 days after national marketing authorization to 74 days; Farmindustria 
data). cOnclusiOns: This new multidisciplinary and multistakeholder approach 
proved to be well-accepted, and the “WEF method” is already recognized as a 
milestone in the Italian HTA landscape, by both Institutions (e.g. AIFA and Italian 
MoH) and Scientific Societies, thus helping payers in making rational decisions 
based on HTA methods.
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ExPloring tHE kEy dEcision drivErs ProvidEd by Hta agEnciEs 
accEPting submissions WitH icErs HigHEr tHan tHE tHrEsHold
Goodrich K., Walsh S.C.M.
HERON Evidence Development Ltd., London, UK
Objectives: Health technology assessment (HTA) agencies use an incremental 
cost-effectiveness ratio (ICER) threshold, generally understood to be £30,000 for 
NICE (England), £20,000 for the SMC (Scotland), CAN$50,000 for CADTH (Canada), 
and AUS$42,000 for PBAC (Australia). To help inform future submissions, we 
assessed the rationale provided by the four HTA agencies when submissions 
were accepted despite the reported ICERs being higher than these thresh-
olds. MethOds: All HTA appraisals from January 2000 to May 2013 from NICE, 
SMC, CADTH, and PBAC were included in the analysis. Multiple technology apprais-
als, resubmissions, vaccination programmes, requests for advice, and submissions 
for which an ICER could not be determined were excluded from the analysis. The 
full responses of the remaining appraisals were reviewed, with the submitted 
ICER (with and without proposed PAS), recommendation, and reasoning behind 
the recommendation extracted. Results: A total of 594 submissions met the 
inclusion criteria and 240 included a higher-than-threshold ICER, with 75 (31.6%) 
accepted. The key rationale for acceptance was a lack of alternative treatments 
(25/75). Submissions were also accepted based on the inclusion of a PAS (21/75), a 
demonstrated cost-effectiveness in a restricted patient population (16/75), and a 
robust economic evaluation resulting in a certain ICER (13/75). The agencies con-
sistently based their rationale on clinical need and cost-effectiveness, although 
the proportions varied between the agencies: NICE (53.3%), SMC (59.4%), CADTH 
(70.0%), PBAC (81.8%). cOnclusiOns: The majority of submissions reporting 
ICERs greater than the threshold ICER were rejected. ICERs over the threshold ICER 
were either brought in line with the threshold ICER through PASs or restricting 
the patient population; or accepted in spite of the high ICER based a clear clinical 
need or a robust and certain economic analysis. This highlights the importance 
for manufacturers to provide robust and appropriately justified economic evalu-
ations, even at the expense of an ICER lower than threshold.
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arE conditionally aPProvEd tHEraPiEs succEssful in gaining markEt 
accEss?
Sweeney N.1, Nijhuis T.1, Haigh J.2
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Objectives: To evaluate all medicines that received a conditional regulatory approval 
in Europe and to compare these decisions with the products current market access 
status through the evaluation of Health Technology Assessments (HTAs). MethOds: 
A manual search of the European Medicines Agencies (EMA) website was carried out 
to identify all pharmaceuticals that received a conditional approval (January 2007 to 
May 2013). Of the medicines identified, the statutory funding status was checked by 
reviewing the websites of the key HTA agencies in the EU 5 countries-: HAS (France), 
G-BA (Germany), AIFA (Italy), DGFPS (Spain) and AWMSG, NICE, SMC (UK). Results: 
A total of 15 pharmaceuticals were found that had received an EMA conditional 
approval. Of these, 10 met the inclusion criteria and were analysed further: etra-
virine, everolimus, fampridine, lapatinib, ofatumumab, panitumumab, pixantrone, 
pazopanib, stiripentol and vandetanib. Of the 10 pharmaceuticals, a total of 50 HTA 
assessments were conducted by the 7 agencies, with 31 (62%) of the HTAs reaching a 
positive funding decision. Both NICE and AWMSG recommended only 1 of the condi-
tionally approved drugs for funding, G-BA recommended 2, SMC 3, DGFPS 6, AIFA 6 and 
HAS 8. Of the 10 drugs, everolimus was the most successful and is funded by 6 (of the 
7) HTA agencies. The key reasons for the success of everolimus were due to convincing 
efficacy (prolonging progression-free survival), combined with an economic case that 
was considered demonstrated despite some uncertainties. cOnclusiOns: Whilst 
regulatory bodies recognise the need to grant marketing authorisation on the basis 
of less complete data, this does not necessarily mean a straight forward path through 
market access. Although the majority of HTA agencies did provide a positive funding 
decision; sound health economic evidence remains essential for new medicines to 
increase the chances of market access approval.
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arE HEad-to-HEad data nEcEssary to gain rEimbursEmEnt in tHE 
frEncH national HEaltH carE systEm?
Patel A.1, Grosfeld D.1, Conti C.C.2, Zaidi Q.1, Furniss S.J.3
1GfK Bridgehead, New York, NY, USA, 2GfK Bridgehead, London, UK, 3GfK Bridgehead, Melton 
Mowbray, UK
bAckgROund: Since December 2011, pharmaceutical companies are required by 
law to provide the Haute Autorité de Santé with head-to-head (H2H) data against 
standard of care when available to be entitled for reimbursement. However, France 
is a market where health authorities rarely deny reimbursement to innovative drugs 
